[go: up one dir, main page]

NO984728L - Enterisk belagte farmas°ytiske sammensetninger av mycofenolat - Google Patents

Enterisk belagte farmas°ytiske sammensetninger av mycofenolat

Info

Publication number
NO984728L
NO984728L NO984728A NO984728A NO984728L NO 984728 L NO984728 L NO 984728L NO 984728 A NO984728 A NO 984728A NO 984728 A NO984728 A NO 984728A NO 984728 L NO984728 L NO 984728L
Authority
NO
Norway
Prior art keywords
mycophenolate
pharmaceutical compositions
enteric coated
coated pharmaceutical
enteric
Prior art date
Application number
NO984728A
Other languages
English (en)
Other versions
NO984728D0 (no
NO322891B1 (no
Inventor
Barbara Haeberlin
Ching Pong Mak
Armin Meinzer
Jacky Vonderscher
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26309105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO984728(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9607564.3A external-priority patent/GB9607564D0/en
Priority claimed from GBGB9622028.0A external-priority patent/GB9622028D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO984728D0 publication Critical patent/NO984728D0/no
Publication of NO984728L publication Critical patent/NO984728L/no
Publication of NO322891B1 publication Critical patent/NO322891B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO19984728A 1996-04-12 1998-10-09 Farmasoytisk sammensetning innbefattende et enterisk belagt mycofenolatsalt samt anvendelse av samme for fremstilling av medikament. NO322891B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9607564.3A GB9607564D0 (en) 1996-04-12 1996-04-12 Organic compounds
GBGB9622028.0A GB9622028D0 (en) 1996-10-24 1996-10-24 Organic compounds
PCT/EP1997/001800 WO1997038689A2 (en) 1996-04-12 1997-04-10 Enteric-coated pharmaceutical compositions of mycophenolate

Publications (3)

Publication Number Publication Date
NO984728D0 NO984728D0 (no) 1998-10-09
NO984728L true NO984728L (no) 1998-12-02
NO322891B1 NO322891B1 (no) 2006-12-18

Family

ID=26309105

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19984728A NO322891B1 (no) 1996-04-12 1998-10-09 Farmasoytisk sammensetning innbefattende et enterisk belagt mycofenolatsalt samt anvendelse av samme for fremstilling av medikament.
NO2007004C NO2007004I2 (no) 1996-04-12 2007-03-26 Farmasoytisk akseptabelt salt av mykofenolsyre

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2007004C NO2007004I2 (no) 1996-04-12 2007-03-26 Farmasoytisk akseptabelt salt av mykofenolsyre

Country Status (34)

Country Link
US (3) US6025391A (no)
EP (2) EP1221316A1 (no)
JP (2) JP3779732B2 (no)
CN (1) CN1104238C (no)
AR (2) AR006583A1 (no)
AT (2) AT408415B (no)
AU (1) AU725388B2 (no)
BE (1) BE1010963A3 (no)
BR (1) BR9708624A (no)
CO (1) CO4900024A1 (no)
CY (1) CY2243B1 (no)
CZ (1) CZ291811B6 (no)
DE (4) DE122004000038I1 (no)
DK (1) DK0892640T3 (no)
ES (2) ES2216141T3 (no)
FR (1) FR2747920B1 (no)
GB (1) GB2326339B (no)
GR (1) GR1002893B (no)
HK (1) HK1051484A1 (no)
HU (1) HU224919B1 (no)
ID (1) ID18663A (no)
IE (1) IE970267A1 (no)
IL (1) IL126431A (no)
IT (1) IT1297045B1 (no)
LU (1) LU91094I2 (no)
MY (1) MY119049A (no)
NL (1) NL300157I2 (no)
NO (2) NO322891B1 (no)
NZ (1) NZ332117A (no)
PT (1) PT892640E (no)
RU (2) RU2203659C2 (no)
TR (1) TR199802056T2 (no)
TW (1) TW457098B (no)
WO (1) WO1997038689A2 (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE474590T1 (de) * 1999-05-10 2010-08-15 Paolo Brenner Kombination von immunsuppressiven substanzen zur behandlung oder vorbeugung von transplantat abstossungen
US20030050692A1 (en) * 2000-12-22 2003-03-13 Avantec Vascular Corporation Delivery of therapeutic capable agents
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
MXPA04003623A (es) * 2001-10-19 2004-12-02 Isotechnika Inc Nuevas formulaciones analogas de ciclosporina.
RU2277090C9 (ru) * 2002-08-29 2006-09-10 Байокон Лимитид Способ получения натриевой соли микофеноловой кислоты, являющейся иммунодепрессантным средством
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
GB0314553D0 (en) * 2003-06-21 2003-07-30 Weatherford Lamb Electric submersible pumps
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
JP5032300B2 (ja) * 2004-03-22 2012-09-26 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 界面活性剤を含有している、リパーゼを含有する生成物の、とりわけパンクレアチンの経口医薬組成物
TW200613294A (en) 2004-04-26 2006-05-01 Teva Gyogyszergyar Reszvenytarsasag Process for preparation of mycophenolic acid and ester derivatives thereof
MXPA06005658A (es) 2004-04-27 2007-04-10 Teva Gyogyszergyar Zartkoruen Proceso para preparacion de micofenolato mofetil, y otros esteres de acido micofenolico.
EP1699773A2 (en) 2004-07-20 2006-09-13 Ceva Gyogyszergyar R Szv Nytarsasag Processes for preparation of crystalline mycophenolate sodium
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
US20060235009A1 (en) 2005-02-08 2006-10-19 Richard Glickman Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors
US20060235070A1 (en) * 2005-02-08 2006-10-19 Hayden Michael R Compositions and methods for treating vascular, autoimmune, and inflammatory diseases
AU2006274835B2 (en) * 2005-07-29 2012-05-24 Abbott Laboratories Gmbh Processes for the manufacture of sterilized pancreatin powder
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
CN1985994B (zh) * 2005-12-19 2011-01-12 康泰乐(北京)医药科技发展有限公司 改进的包含霉酚酸盐的包有肠溶衣的药物组合物
US20090023805A1 (en) * 2006-02-13 2009-01-22 Anne Claire Marrast Method of administration
JP2007230948A (ja) * 2006-03-02 2007-09-13 Univ Meijo 腸溶性化硬カプセル
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
EP2032712B1 (en) * 2006-06-29 2010-02-10 Ivax Pharmaceuticals S.R.O. Regulation of acid metabolite production
US20080176937A1 (en) * 2007-01-23 2008-07-24 Apotex Fermentation Inc. Novel crystalline mycophenolate sodium polymorph and processes to manufacture same
US20080182998A1 (en) * 2007-01-25 2008-07-31 Apotex Fermentation Inc. Novel crystalline mycophenolate sodium polymorph and processes to manufacture same
US20080254520A1 (en) * 2007-04-11 2008-10-16 Eva Gulyas Method for reducing impurity level in mycophenolic acid fermentation
EP2187872A4 (en) 2007-08-13 2013-09-18 Panacea Biotec Ltd EXTENDED RELEASE COMPOSITIONS COMPRISING SODIUM MYCOPHENOLATE AND METHODS RELATING THERETO
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
CN102099029A (zh) * 2008-07-09 2011-06-15 阿斯普瑞瓦国际公司 治疗眼部病症的霉酚酸钠的pH值特定溶液
EA201270544A1 (ru) * 2009-10-13 2012-09-28 Тева Фармасьютикал Индастриз Лтд. Композиции с отсроченным высвобождением
US20110086102A1 (en) * 2009-10-13 2011-04-14 Teva Pharmaceutical Industries Ltd. Delayed release compositions
WO2011051967A2 (en) * 2009-10-23 2011-05-05 Alkem Laboratories Ltd Pharmaceutical compositions comprising mycophenolate and processes for preparing thereof
CN103880799A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
CN103880800A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
GB201100786D0 (en) 2011-01-18 2011-03-02 Ems Sa Pharmaceutical compositions of immunosuppressants
WO2013041205A1 (de) 2011-09-19 2013-03-28 Pyxirion Pharma Gmbh Neue therapeutische konzepte zur behandlung von gefässerkrankungen
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
JP6373353B2 (ja) 2013-03-14 2018-08-15 アルカーメス ファーマ アイルランド リミテッド フマル酸エステルのプロドラッグおよび種々の疾患の治療におけるその使用
WO2014167442A1 (en) 2013-03-26 2014-10-16 Wockhardt Limited Pharmaceutical compositions comprising mycophenolic acid or salts thereof
AU2015204192B2 (en) 2014-01-06 2020-03-26 Shield TX (UK) Limited Dosage regimen of ferric trimaltol
WO2015127450A1 (en) 2014-02-24 2015-08-27 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
GB201418710D0 (en) 2014-10-21 2014-12-03 Iron Therapeutics Holdings Ag Dosage regimen
US10213411B2 (en) 2015-08-27 2019-02-26 Vijaykumar Rajasekhar Use of prodrugs of fumarates in treating heart failure diseases
US10463642B2 (en) 2016-02-01 2019-11-05 Vijaykumar Rajasekhar Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate
CA3054817A1 (en) * 2017-03-13 2018-09-20 Okava Pharmaceuticals, Inc. Methods and compositions for delivering mycophenolic acid active agents to non-human mammals
WO2022187379A1 (en) 2021-03-03 2022-09-09 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions
CN114028334B (zh) * 2021-12-10 2023-08-29 卓和药业集团股份有限公司 一种肺部给药的免疫抑制剂的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1157100A (en) * 1966-09-27 1969-07-02 Ici Ltd Pharmaceutical Compositions
GB1157099A (en) * 1966-09-27 1969-07-02 Ici Ltd Fermentation Process
GB1173942A (en) * 1967-06-06 1969-12-10 Bellon Labor Sa Roger New 2,3-Dihydro-1,4-Benzoxazines
GB1158387A (en) * 1967-06-13 1969-07-16 Ici Ltd Procedure for Isolation of Mycophenolic Acid
GB1203328A (en) * 1968-06-04 1970-08-26 Ici Ltd Pharmaceutical compositions
GB1261060A (en) * 1969-09-09 1972-01-19 Ici Ltd Phthalen-1-one derivatives
US3705946A (en) * 1971-05-25 1972-12-12 Lilly Co Eli Method of treating hyperuricemia
JPS5542995B2 (no) * 1972-02-24 1980-11-04
US3825571A (en) * 1971-07-31 1974-07-23 Chugai Pharmaceutical Co Ltd Mycophenolic acid derivatives
US3868454A (en) * 1972-08-14 1975-02-25 Lilly Co Eli Psoriasis treatment with mycophenolic acid derivatives
US3777020A (en) * 1972-08-14 1973-12-04 Lilly Co Eli Psoriasis treatment with mycophenolic acid
US4005108A (en) * 1973-04-03 1977-01-25 Research Corporation Novel anti-leukemic diterpenoid triepoxides
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
US3903071A (en) * 1973-05-22 1975-09-02 Lilly Co Eli Mycophenolic acid derivatives
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
US4234684A (en) * 1979-12-11 1980-11-18 Eli Lilly And Company Method of preparing mycophenolic acid glucoside
IT1150194B (it) * 1982-02-23 1986-12-10 Chiesi Farma Spa Formulazioni farmaceutiche ad attivita'antiinfiammatoria, analgesica,antipiretica e gastroprotettiva
US4680299A (en) * 1984-04-30 1987-07-14 E.I. Du Pont De Nemours And Company 2-phenyl-4-quinolinecarboxylic acids and pharmaceutical compositions thereof
US4686234A (en) * 1985-11-27 1987-08-11 Syntex (U.S.A) Inc. Mycophenolic acid derivatives in the treatment of inflammatory diseases, in particular rheumatoid arthritis
US4959387A (en) * 1986-01-23 1990-09-25 Syntex (U.S.A.) Inc. Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US4725622A (en) * 1986-01-23 1988-02-16 Syntex (U.S.A.) Inc. Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US4727069A (en) * 1987-01-30 1988-02-23 Syntex (U.S.A.) Inc. Heterocyclic aminoalkyl esters of mycophenolic acid, derivatives thereof and pharmaceutical compositions
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
US4847381A (en) * 1987-08-31 1989-07-11 American Cyanamid Company 2-Phenyl-4-quinoline carboxylic acids
US5135934A (en) * 1990-07-06 1992-08-04 Du Pont Merck Pharmaceutical Company 3-phenyl-5,6-dihydrobenz(c) acridine-7-carboxylic acids and related compounds as immunosuppressive agents
US5372298A (en) * 1992-01-07 1994-12-13 The Regents Of The University Of California Transient liquid phase ceramic bonding
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
WO1994026265A1 (en) * 1993-05-06 1994-11-24 Pharmagenesis, Inc. 16-hydroxytriptolide composition and method for immunotherapy
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
US5428040A (en) * 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
UA39962C2 (uk) * 1993-10-01 2001-07-16 Сінтекс ( С.Ш.А. ) Інк. Фармацевтична композиція, яка містить мофетил мікофеноляту, для орального введення ( варіанти ) та спосіб її одержання ( варіанти )
AU5594794A (en) * 1993-11-08 1995-05-29 Pharmagenesis, Inc. Immunotherapy composition and method
EP0729471A1 (en) * 1993-11-19 1996-09-04 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators

Also Published As

Publication number Publication date
IL126431A0 (en) 1999-08-17
CN1104238C (zh) 2003-04-02
HK1016490A1 (en) 1999-11-05
NO984728D0 (no) 1998-10-09
IE970267A1 (en) 1997-10-22
JP2006063086A (ja) 2006-03-09
HU224919B1 (en) 2006-04-28
US6025391A (en) 2000-02-15
ATA905997A (de) 2001-04-15
EP1221316A1 (en) 2002-07-10
DE69727559T2 (de) 2004-12-16
TR199802056T2 (xx) 1999-02-22
RU2203659C2 (ru) 2003-05-10
AT408415B (de) 2001-11-26
ES2178510B1 (es) 2004-08-16
EP0892640A2 (en) 1999-01-27
JP2000503665A (ja) 2000-03-28
HUP9903373A2 (hu) 2001-04-28
RU2615397C2 (ru) 2017-04-04
WO1997038689A2 (en) 1997-10-23
NO2007004I2 (no) 2009-10-19
NO322891B1 (no) 2006-12-18
MY119049A (en) 2005-03-31
NL300157I2 (nl) 2004-12-01
NO2007004I1 (no) 2007-04-16
AR059693A2 (es) 2008-04-23
NL300157I1 (nl) 2004-10-01
DE122004000038I2 (de) 2006-04-27
IT1297045B1 (it) 1999-08-03
US6172107B1 (en) 2001-01-09
PT892640E (pt) 2004-06-30
TW457098B (en) 2001-10-01
HK1051484A1 (en) 2003-08-08
DE69727559D1 (de) 2004-03-18
CO4900024A1 (es) 2000-03-27
AU2384397A (en) 1997-11-07
CY2243B1 (en) 2003-07-04
IL126431A (en) 2005-03-20
US6306900B1 (en) 2001-10-23
FR2747920A1 (fr) 1997-10-31
DE122004000038I1 (de) 2006-01-26
DK0892640T3 (da) 2004-05-10
ES2216141T3 (es) 2004-10-16
GB2326339A (en) 1998-12-23
CN1215991A (zh) 1999-05-05
FR2747920B1 (fr) 1999-12-31
EP0892640B1 (en) 2004-02-11
GB2326339B (en) 2000-04-19
GR1002893B (el) 1998-04-10
CZ291811B6 (cs) 2003-06-18
BR9708624A (pt) 1999-08-03
WO1997038689A3 (en) 1997-12-04
BE1010963A3 (fr) 1999-03-02
NZ332117A (en) 2000-04-28
ES2178510A1 (es) 2002-12-16
LU91094I2 (fr) 2004-10-11
JP3779732B2 (ja) 2006-05-31
CZ326798A3 (cs) 1999-01-13
AU725388B2 (en) 2000-10-12
DE19781690D2 (de) 1999-04-08
GB9821304D0 (en) 1998-11-25
HUP9903373A3 (en) 2001-05-28
ITRM970207A1 (it) 1998-10-11
AR006583A1 (es) 1999-09-08
ID18663A (id) 1998-04-30
ATE259228T1 (de) 2004-02-15

Similar Documents

Publication Publication Date Title
NO984728L (no) Enterisk belagte farmas°ytiske sammensetninger av mycofenolat
NO20000300D0 (no) Hydrogenolyse av glycerol
NO990059L (no) Analoger av kationiske proteiner
NO993068L (no) Ny forbindelsesform
FI972555L (fi) Päällystettyjen tablettien valmistus
NO995852L (no) Ny form av S-omeprazol
NO992875D0 (no) Fremstilling av enantiomert anriket threo-metylfenidat
NO20002279D0 (no) Sammensetninger av lipidsenkende midler
ID18832A (id) Komposisi insektisida
ID16838A (id) Komposisi dekafluoropentana
ID17419A (id) Komposisi dekafluoropentana
NO991148L (no) Fremstilling av 1-butyl-4-piperidinyl-metylamin
ID23774A (id) Komposisi insektisida
FI991343A0 (fi) Dihydropolyprenolien öljykoostumus
SI0892640T1 (en) Enteric-coated pharmaceutical compositions of mycophenolate
FI963415A0 (fi) Packning av hushaollsvaetskekartonger och -toravfall
NO994977D0 (no) Fremstilling av enantiomerfrie biarylketokarboksylsyrer
SE9704083D0 (sv) Framställning av bioenergiprodukter
BR1100567A (pt) Composição farmacêutica de 3-aminoquinuclidina substituìda
ZA973116B (en) Enteric coated pharmaceutical composition
SE9600037D0 (sv) Modifiering av cement
KR970056487U (ko) 분무기동체의 개량구조
FI971644A0 (fi) Konstruktionsenhet av trae
ID19538A (id) Tempat kemeja

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: MYFORTIC; NAT. REG. NO/DATE: 03-2258 OG 03-2259 20040319; FIRST REG. NO/DATE: LI , 5611501/02 20021024

Spc suppl protection certif: 2007004

Filing date: 20070326

Extension date: 20171024

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: MYFORTIC; NAT. REG. NO/DATE: 03-2258 OG 03-2259 20040319; FIRST REG. NO/DATE: LI , 5611501/02 20021024

Spc suppl protection certif: 2007004

Filing date: 20070326

Extension date: 20171024

MK1K Patent expired
SPCX Expiry of an spc

Spc suppl protection certif: 2007004

Effective date: 20171024